38 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-887364 Apr 24, 2020 - Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Is a Beat in Store for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/887540/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-887540 Apr 24, 2020 - Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.
ASM International NV (ASMIY) CEO Chuck del Prado on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4339222-asm-international-nv-asmiy-ceo-chuck-del-prado-on-q1-2020-results-earnings-call-transcript?source=feed_sector_transcripts Apr 22, 2020 - ASM International NV (OTCQX:ASMIY) Q1 2020 Results Conference Call April 22, 2020 09:00 AM ET Company Participants Victor Bareño - Director of Investor Relations Chuck del Prado - Chief Executive Offi
ASM International NV 2020 Q1 - Results - Earnings Call Presentation https://seekingalpha.com/article/4339157-asm-international-nv-2020-q1-results-earnings-call-presentation?source=feed_all_articles Apr 22, 2020 - The following slide deck was published by ASM International NV in conjunction with their 2020 Q1 earnings call.
Akzo Nobel NV (AKZOF) CEO Thierry Vanlancker on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4339104-akzo-nobel-nv-akzof-ceo-thierry-vanlancker-on-q1-2020-results-earnings-call-transcript?source=feed_sector_transcripts Apr 22, 2020 - Akzo Nobel NV (OTCQX:AKZOF) Q1 2020 Earnings Conference Call April 22, 2020, 03:00 ET Company Participants Lloyd Midwinter - Director of Communications & Investor Relation Thierry Vanlancker - Cha
What's The Best Biotech Stock to Buy for Treating Sickle Cell Disease? https://www.fool.com/investing/2020/04/22/whats-the-best-biotech-stock-to-buy-for-treating-s.aspx?source=iedfolrf0000001 Apr 22, 2020 - Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs http://www.zacks.com/stock/news/883666/roche-rhhby-q1-sales-grow-on-solid-performance-of-new-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-883666 Apr 22, 2020 - Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings? http://www.zacks.com/stock/news/882090/can-lilly-lly-deliver-a-beat-in-coronavirus-hit-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-882090 Apr 21, 2020 - Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.
Why Earnings Season Could Be Great for Novartis (NVS) http://www.zacks.com/stock/news/882027/why-earnings-season-could-be-great-for-novartis-nvs?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-882027 Apr 21, 2020 - Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up http://www.zacks.com/stock/news/882015/alexion-to-evaluate-rare-disease-drug-for-covid-19-shares-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-882015 Apr 21, 2020 - Alexion (ALXN) gains as it announces plans to initiate a study to evaluate Ultomiris for the COVID-19 infection.

Pages: 1234

<Page 2>